Eric Benevich - Nov 30, 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Nov 30, 2022
Transactions value $
-$6,295,085
Form type
4
Date filed
12/1/2022, 05:43 PM
Previous filing
Nov 10, 2022
Next filing
Jan 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $926K +22.2K +141.67% $41.78 37.8K Nov 30, 2022 Direct
transaction NBIX Common Stock Sale -$2.79M -22.2K -58.62% $125.90 15.6K Nov 30, 2022 Direct F1, F2
transaction NBIX Common Stock Options Exercise $280K +7.78K +49.7% $35.99 23.4K Nov 30, 2022 Direct
transaction NBIX Common Stock Sale -$979K -7.78K -33.2% $125.90 15.6K Nov 30, 2022 Direct F1, F2
transaction NBIX Common Stock Options Exercise $868K +20.1K +128.26% $43.24 35.7K Nov 30, 2022 Direct
transaction NBIX Common Stock Sale -$2.53M -20.1K -56.19% $125.90 15.6K Nov 30, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise -$926K -22.2K -100% $41.78 0 Nov 30, 2022 Common Stock 22.2K $41.78 Direct F3
transaction NBIX Non-Qualified Stock Option Options Exercise -$280K -7.78K -100% $35.99 0 Nov 30, 2022 Common Stock 7.78K $35.99 Direct F4
transaction NBIX Non-Qualified Stock Option Options Exercise -$868K -20.1K -27.26% $43.24 53.5K Nov 30, 2022 Common Stock 20.1K $43.24 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $126.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016.
F4 Option granted February 05, 2016 and vested monthly over four years.
F5 Option granted February 06, 2017 and vested monthly over four years.